T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Mettler-Toledo International
MTD
$28.6B
| $159M | 0.02% |
137,584
-2,458
| -2% | -$2.85M |
|
627
CRISPR Therapeutics
CRSP
$5.2B
| $158M | 0.02% |
1,298,329
-476,107
| -27% | -$71.9M |
|
|
GBT
628
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $158M | 0.02% |
3,874,066
-189,057
| -5% | -$8.69M |
|
629
Arvinas
ARVN
$581M
| $158M | 0.02% |
2,386,455
+141,006
| +6% | +$10.8M |
|
630
New Oriental
EDU
$8.33B
| $158M | 0.02% |
1,126,140
+745,538
| +196% | +$130M |
|
|
APLS
631
DELISTED
Apellis Pharmaceuticals
APLS
| $156M | 0.02% |
3,642,149
+596,820
| +20% | +$28.2M |
|
|
AESC
632
DELISTED
The AES Corporation
AESC
| $156M | 0.02% |
+1,516,303
| New | +$155M |
|
633
Consolidated Edison
ED
$40B
| $155M | 0.02% |
2,075,987
+1,489,003
| +254% | +$105M |
|
634
Fox Class A
FOXA
$27.1B
| $155M | 0.02% |
4,282,958
+737,316
| +21% | +$25.8M |
|
635
Atea Pharmaceuticals
AVIR
$410M
| $154M | 0.02% |
2,561,375
+43,398
| +2% | +$2.93M |
|
636
Agios Pharmaceuticals
AGIO
$2B
| $153M | 0.02% |
2,960,412
-11,910
| -0.4% | -$590K |
|
|
CHX
637
DELISTED
ChampionX
CHX
| $152M | 0.02% |
7,007,340
-60,263
| -0.9% | -$1.17M |
|
638
RenaissanceRe
RNR
$13.3B
| $152M | 0.02% |
949,215
+878,478
| +1,242% | +$142M |
|
639
United Airlines
UAL
$41.2B
| $152M | 0.02% |
2,636,052
-246,361
| -9% | -$12M |
|
640
ICICI Bank
IBN
$106B
| $152M | 0.02% |
9,454,777
+592,485
| +7% | +$9.68M |
|
|
NBIS
641
Nebius Group N.V.
NBIS
$68.2B
| $151M | 0.02% |
2,350,078
+220,333
| +10% | +$14.7M |
|
642
10x Genomics
TXG
$7.63B
| $150M | 0.02% |
831,103
-25,183
| -3% | -$4.35M |
|
|
WBA
643
DELISTED
Walgreens Boots Alliance
WBA
| $150M | 0.02% |
2,736,639
+1,482,468
| +118% | +$73.3M |
|
644
Delta Air Lines
DAL
$60.2B
| $150M | 0.02% |
3,110,785
+829,564
| +36% | +$36.7M |
|
645
Novavax
NVAX
$1.34B
| $149M | 0.01% |
822,768
+476,750
| +138% | +$95M |
|
|
BECN
646
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $149M | 0.01% |
2,841,579
-14,263
| -0.5% | -$666K |
|
647
AtriCure
ATRC
$2.21B
| $148M | 0.01% |
2,265,628
-65,805
| -3% | -$4.05M |
|
648
Expro Ltd
XPRO
$2.07B
| $148M | 0.01% |
6,960,970
+284,114
| +4% | +$6.18M |
|
649
Hanover Insurance
THG
$7.74B
| $148M | 0.01% |
1,142,767
+57,223
| +5% | +$6.9M |
|
650
NVR
NVR
$16.9B
| $148M | 0.01% |
31,333
+995
| +3% | +$4.47M |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.